Results of autologous transplantation for multiple myeloma (MM) in Austria. An analysis based on data from the Austrian Stem Cell Transplantation (ASCT) Registry

6657 Background: Median survival with conventional therapy in MM is usually less than 40 months. Two prospective randomised trials (IFM 90 and MRC trial) showed superiority of high-dose therapy with autologous SCT over conventional treatment, although other trials were unable to confirm a statistical significant benefit. Here we report the results of high dose chemotherapy in all patients (> 99.5%) with MM treated in Austria. Methods: 324 patients treated with autologous SCT from 1989 onwards have retrospectively been analysed. Median age: 55.6 years (range 24.6 –70.7 years). Peripheral blood stem cells were used in 317 and bone-marrow derived stem cells in 7 patients. 170 patients were treated with single (ST) and 98 with double transplantation (DT), while all other patients received >2 autografts during the whole course of their disease. The influence of total body irradiation (TBI) and interferon (IFN) maintenance was also analysed. All but one patient were evaluable for survival, and 265 patients were...